Combination Therapy for AML and Challenges in Translating Successful Treatment Strategies

This chapter explores the potential of combination therapy for MDS of ASIMAGRO and TP53 AML, as well as the challenges in translating successful treatment strategies from B-cell lymphoblasia and ALL to other entities. It discusses the correlation between biomarker aspects, tumor burden, and response rates in emerging immunotherapies for AML, and explores the potential of using bispecific strategies in earlier lines of treatment. The chapter emphasizes the need for improvement and identification of the optimal patient setting in AML treatment.